Skip to search formSkip to main contentSkip to account menu

lumiliximab

Known as: p5E8, monoclonal antibody lumiliximab, anti-CD23 Antibody 
IDEC-152 was developed to decrease the body's response to allergens, thereby affecting diseases related to asthma and allergic disorders. This… 
National Institutes of Health

Related topics

Related topics

4 relations
IDEC-152antigen bindingcyclophosphamide/fludarabine/lumiliximab/rituximab

Broader (1)

Monoclonal Antibodies

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2010
Review
2010
Novel agents for the treatment of chronic lymphocytic leukemia.
Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world. Currently, the most effective treatment for… 
2009
2009
Lumiliximab Triggers Apoptosis Mechanisms in CLL Cells through the Inhibition of PI3-K/Akt Pathway.
Abstract 2371 Poster Board II-348 Chronic lymphocytic leukemia (CLL) is a clonal expansion of B cells which is characterized by a… 
2008
2008
Lumiliximab in combination with FCR for the treatment of relapsed chronic lymphocytic leukemia (CLL): results from a phase I/II multicenter study
7003 Background: Lumiliximab is an anti-CD23 monoclonal antibody that is being investigated for the treatment of relapsed B-cell… 
2008
2008
Correlation of clinical activity of lumiliximab in combination with FCR and ZAP 70 expression on B-cell chronic lymphocytic leukemia cells
7073 Background: Lumiliximab is an anti-CD23 monoclonal antibody under investigation for the treatment of patients with relapsed… 
2008
2008
Lumiliximab, An Apoptosis Sensitizer to Multiple CLL Therapeutic Agents
Chronic lymphocytic leukemia (CLL) is a B cell malignancy characterized by the accumulation of mature phenotype leukemic B cells… 
2008
2008
Anti-Drug Antibody Responses to Lumiliximab Are Not Detected in Relapsed Refractory CLL Patients Treated with Lumiliximab in Combination with FCR in a Phase 1/II Study
Lumiliximab, an anti-CD23 monoclonal antibody that binds specifically to human CD23, is under investigation for the treatment of… 
2006
2006
Comparison of Results from a Phase 1/2 Study of Lumiliximab (Anti-CD23) in Combination with FCR for Patients with Relapsed CLL with Published FCR Results.
Lumiliximab is a PRIMATIZED® anti-CD23 monoclonal antibody with human IgG1 constant regions and macaque variable regions… 
2006
2006
Lumiliximab with fludarabine, cyclophosphamide, and rituximab (FCR) for patients with relapsed chronic lymphocytic leukemia (CLL).
6597 Background: Lumiliximab, an anti-CD23 monoclonal antibody, had pharmacologic activity and an outstanding safety profile in a… 
Review
2004
Review
2004
Technology evaluation: lumiliximab, Biogen Idec.
  • J. Reichert
  • Current opinion in molecular therapeutics (Print)
  • 2004
  • Corpus ID: 42304397
Biogen Idec (formerly IDEC Pharmaceuticals) is developing lumiliximab, a primatized anti-CD23 macaque/human chimeric antibody… 
2004
2004
Pharmacokinetics of Single-Agent Lumiliximab (Anti-CD23 Antibody) in Patients with Chronic Lymphocytic Leukemia.
CD23 is highly expressed on the cell surface of certain B-cell malignancies including chronic lymphocytic leukemia (CLL… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)